PhorMed

Utilizing Gene Repair to Treat Diseases

PhorMed

Utilizing Gene Repair to Treat Diseases

Century City, CA
Biotechnology
PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. We are working to utilize gene therapy to treat diseases, allowing the body to begin healing itself, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma, Parkinson’s disease, and viruses.

$1,878,972

raised
3,354
Investors
$39M
Valuation
$1.00
Price per Share
$250.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$5M
Offering Max
Reg CF
Offering

$1,878,972

raised
3,354
Investors
$39M
Valuation
$1.00
Price per Share
$250.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$5M
Offering Max
Reg CF
Offering

Rewards

Get rewarded for investing more into PhorMed:

$250+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$500+
Investment
5% Bonus Shares
Invest $500+ and receive 5% bonus shares & access to our Investor Club which allows you to vote on drug names, receive special investor updates, and attend Q&A sessions
$1,500+
Investment
10% Bonus Shares
Invest $1,500+ and receive 10% bonus shares & access to our Investor Club.
$5,000+
Investment
15% Bonus Shares
Invest $5,000+ and receive 15% bonus shares & access to our Investor Club.
$10,000+
Investment
20% Bonus Shares
Invest $10,000+ and receive 20% bonus shares, an in-person meeting with the leadership team**, and access to our Investor Club.

Reasons to Invest

Current first-line treatment options have severe side-effects and can be toxic; our technology targets the disease not just the symptoms
Exciting technology with the potential to treat multiple diseases means expanding opportunities for new markets and the potential for growth
The combined potential market is $8B+ per year

Title


Many common life-threatening diseases require dangerous treatments that have long-lasting side-effects or few options


Patients suffering from Acute Myeloid Leukemia (AML), Hodgkin’s Lymphoma (HL), Parkinson’s disease (PD), and COVID-19 are faced with either the reality of no realistic treatment options or for some diseases like cancer, potentially harmful and painful treatments with long-lasting side-effects.

We believe our early-stage drug shows unparalleled promise in the treatment of diseases


We are in the midst of clinical trials with our proprietary drug that will potentially be able to treat patients diagnosed with AML, HL, PD, COVID-19 and other projected diseases. Our technology, RP-323 works to “repair” the damaged cellular processes at the molecular level.

Unfortunately, these deadly diseases are wide-spread


The world market for drugs treating HL is projected to post a compound annual growth rate (CAGR) of 16% over the next four years. The same projections expect the market to reach $1.4B by 2024.


The CAGR of the AML market is expected to be around 14% over the next five years, and is expected to top $1.5B by 2024.


The PD therapeutics world market was valued at over $2B in 2016 and is expected to rise with a CAGR of 10.9% from 2017 to 2025.


Combined, the total annual market for three of our drug’s potential uses could reach close to $8B by 2025.


The COVID-19 market is still to be determined.


Our drug has been proven to be safe in early studies


The Safety Study has been completed establishing the validity and effectiveness of our drug. We are allocating Research & Development funds and are actively proceeding with next steps and clinical trials for all indications.


Our goal is to complete Phase II in all of our clinical trials.

We focus on treating the disease rather than the symptoms


RP-323 utilizes gene repair therapy to target damaged or mutated cells and repair a broad range of cell types. Our technology focuses on the root cause, aiming to fix the cellular damage on a molecular level. 


The drug will be administered through intravenous infusion (I.V drip), as an out-patient treatment, unless otherwise suggested by the physician.

Our financial directives are value-driven creating multiple potential exit strategies for our investors


PhorMed will be open to a variety of exit strategies including but not limited to a go-public transaction, partnering with a Pharmaceutical or Biotech company through a distribution deal, or through a merger or acquisition.


All options will be considered based on the best outcome for our investors and the company, and the timing of these potential options is yet to be determined.

Our treatments are non-toxic and have very few side effects


Current treatment options for some diseases have long-lasting and potentially devastating side effects because those treatments can damage or kill healthy cells.


Treatment recipients are not required to remain in the hospital thanks to the limited side effects and unobtrusive nature of the drug. We believe our treatment will be a safer, non-toxic alternative for a variety of applications including cancer, viruses and neurological disorders.

We are driven to fulfill unmet medical needs


Phase II Clinical Trials are targeted for completion in the next 2.5 years. During the same period, the goal is to complete multiple licensing deals with pharmaceutical and/or biotech companies. We believe these major steps would precipitate expansion of our pipeline and the potential placement of multiple products in the marketplace.


We anticipate that in the next 3-4 years our company will be able to take advantage of the growing market and help fulfill unmet medical needs.

We believe our drug can drastically improve the quality of life for our patients


We have an opportunity to forever change the options facing patients suffering from these awful diseases. With treatment from our drug, we believe these patients will be able to take back their lives, and won’t be saddled with long-lasting side effects, or be required to live in the hospital for weeks on end.


The company anticipates a clear path toward an open and ever-growing marketplace. Through potential partnerships and a number of other possible exit strategies, we are confident in our ability to fulfill the market's need for new and safe treatment options.


THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS.  INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

Quick Insert

Offering Summary


Company

:

Phormed Inc

Corporate Address

:

1999 Avenue of the Stars, #1100, Century City, CA 90067

Offering Minimum

:

$10,000.00

Offering Maximum

:

$5,000,000.00

Minimum Investment Amount

(per investor)

:

$250.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

10,000

Maximum Number of Shares Offered

:

5,000,000

Price per Share

:

$1.00

Pre-Money Valuation

:

$39,000,000.00











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Time-Based Bonuses*:

  • Invest within the 1st week and receive 20% bonus shares.
  • Invest within the 2nd week and receive 15% bonus shares.
  • Invest within the 3rd week and receive 10% bonus shares.
  • Invest within the 4th week and receive 5% bonus shares.
  • New Year's Bonus - Invest between Jan 1st, 2020 and Jan 3rd, 2020 and receive 15% bonus shares

Volume Based Bonuses and Perks*:

  •  Invest >$500, you will receive 5% bonus shares & access to our Investor Club which allows you to vote on drug names, receive special investor updates, and attend Q&A sessions 
  • If you invest >$1,500, you will receive 10% bonus shares & access to our Investor Club.
  • If you invest >$5,000, you will receive 15% bonus shares & access to our Investor Club.
  • If you invest >$10,000, you will receive 20% bonus shares, an in-person meeting with the leadership team**, and access to our Investor Club.

*Investors cannot qualify for both bonuses in any single investment. If an investor qualifies for two bonuses the higher of the two bonuses will be applied. All perks occur after the offering is completed.

**Travel Not Included

The 10% Bonus for StartEngine Shareholders

Phormed Inc will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 Common Stock shares, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$340,922.00 USD
$350.00 USD
Cash And Cash Equivalents
$109,844.00 USD
$350.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$363,294.00 USD
$34,083.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$948,160.00 USD
-$72,700.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Notice of Funds Disbursement

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Campaign is extending for 90 days


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Material Change in Offering

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Campaign is extending for 90 days


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

VACCINE AND TREATMENT FOR COVID-19

about 2 months ago

Graphical user interface, background pattern

Description automatically generated

 

With the global focus on the COVID-19 pandemic and vaccines, we felt it was important to definitively explain PhorMed’s foray into the battle against COVID-19. We are posting this update to define the differences between vaccines and treatments related to the coronavirus disease (COVID-19), and to inform you that we are developing a treatment rather than a vaccine.  

 

Traditional vaccines work by introducing inactive components of a specific organism/virus that the vaccine is designed to treat, which triggers a response from the body’s immune system. Newer vaccines do not contain the actual organism, but rather a blueprint, or set of instructions to trigger this same response from the immune systems, a single strand RNA. Regardless of the vaccine, the concept is to cause a reaction from the immune system that creates anti-bodies against the targeted virus, which is designed to give the body a defense against future infections from that disease. 

 

Unlike vaccines which are designed to build a resistance to the virus, the goal of our research in this area is to develop a treatment for those patients who suffer from inflammatory symptoms as a result of the COVID-19 infection. One of the dangerous symptoms of the COVID-19 infection are lung-related issues, and the potentially devastating condition known as Acute Respiratory Distress Symptom (ARDS). People who develop this condition have difficulty breathing, sometimes are unable to breath on their own, and can lead to death. Using genomic medicine, and our drug’s ability to battle inflammatory issues, we made the decision to expand our pipeline to include COVID-19, ARDS, Anti-Virus and Suppression of Pulmonary Inflammation.

 

As always, we would like to thank and welcome our current and new investors, and the people who have followed our campaign. If you have not yet invested in PhorMed, please consider investing now and sharing information about our technology with others.

 

Thank you all and be well,

 

Stuart Greene

Vice President of Marketing & Business Development

Notice of Funds Disbursement

about 2 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

PLATFORM TECHNOLOGY DEFINED

2 months ago

PLATFORM TECHNOLOGY DEFINED

Graphical user interface, background pattern

Description automatically generated

Platform Technology Defined

This update is specifically targeted towards the understanding of Platform Technology. It is used in various ways within the scientific and medical industries, and we believe it is important to define our specific use of this terminology as it pertains to our technology.

RP-323, is a small molecule drug which can potentially treat a number of diseases, allowing us to expand our pipeline without the need of new drug discoveries. If you have been following our campaign, you may have seen this when we addressed the COVID-19 crisis. This ability of our single compound, RP-323, to treat multiple diseases is the reason for its classification as a Platform Technology. This capability for multiple uses can allow us to increase the pipeline, potentially creating a dominant intellectual property position, offering multiple shots at end target and possible increased future revenues.

Over the course of our campaign, we have received and responded to several questions asking if we intend to address specific diseases and medical challenges which are not in our current pipeline, which presently includes COVID-19, Acute Myeloid Leukemia, Hodgkin’s Lymphoma, and Parkinson’s disease. These comments have included requests for targeting amyotrophic lateral sclerosis (ALS), prostate cancers, human immunodeficiency virus (HIV), and even ageing. As a company, it is our sincere hope that additional indications could be added to our pipeline in the future as the stories we receive from people who suffer from disease directly, or through family and friends, are continual reminders of why we became involved in this business.

PhorMed continues to strive towards the development of treatment options that will offer hope to those who suffer from diseases with few other options. 

We would like to thank all our current and new investors, and all the people who have followed our campaign. For those who have already invested, we thank you. If you have not yet invested in PhorMed, please consider investing now to join us on this journey forward. 

 

Thank you all and be well,

 

Stuart Greene

Vice President of Marketing & Business Development

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

4 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


PhorMed is extending their campaign by 90 days.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

5 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

5 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

7 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

OFFERING MAX INCREASED TO $5 MILLION

7 months ago

A picture containing wheel, drawing

Description automatically generatedPhorMed

OFFERING MAX INCREASED TO $5 MILLION

 

PhorMed is excited to announce that after working through the SEC requirements we are now successfully back on track with our crowdfunding efforts. We have increased our raise to $5 Million! We would like to thank all our existing investors and all those who continued to invest on the waitlist.

 

To all our Waitlist investors, please make sure you respond to StartEngine emails to confirm your purchase of shares, in order to ensure that you secure your investment.

 

Thank you for your support,

 

Stuart Greene

VP of Marketing and Business Development

MCCOY MORETZ, M.D.

7 months ago

A picture containing wheel, drawing

Description automatically generatedPhorMed

MCCOY MORETZ, M.D.

 

It is with great sadness that we announce the passing of “Dr. Mac,” McCoy Moritz, M.D., who died unexpectedly after a brief illness. The entire PhorMed family mourns his loss and extends our deepest sympathies to his family. Dr. Moritz was a brilliant and compassionate physician and medical researcher who brought great dedication to his stewardship of PhorMed as its Chief Executive Officer (CEO) and Chief Medical Officer (CMO).

Ben Chang, President, Chief Financial Officer (CFO), Chairman and Co-Founder, will step in as interim CEO and continues to oversee the day-to-day management of the company. A graduate of East Carolina University with a degree in Economics and International Finance, Ben has over 26 years of pharmaceutical and executive experience. He is also co-inventor of the PhorMed Anti-Virus/COVID-19 patent.

Dr. Sean O’Connell will step up from his seat on the PhorMed Scientific and Medical Advisory Board to serve as Chief Medical Officer (CMO). 

Dr. O’Connell received his Ph.D. in Immunology and Molecular Biology from Rutgers University. As a post-doctoral fellow at Rutgers University School of Pharmacy, he worked closely with Dr. Richard Chang, conducting a variety of studies on the action of TPA on promyeloid bone marrow cells. 

A seasoned healthcare professional with over 65 peer-reviewed publications, Dr. O’Connell has steered numerous venture capital, pharmaceutical, biotechnology, medical device and tissue processing companies through pre-clinical and clinical development, commercial opportunity assessment, all the way through product and marketing development. Dr. O’Connell met Dr. Moritz as part of a team of surgeons working at Chang’an Hospital in Xi’an, China. Together they developed an autologous stem cell therapy to treat a variety of deleterious skin conditions.

“Dr. Mac contributed immensely to the establishment and growth of PhorMed,” said Ben Chang. “His knowledge, drive, and friendship will be profoundly missed. On behalf of the entire PhorMed family, I would like to reiterate our commitment to seeing his visions realized.”

                                    

Notice of Material Change in Offering

7 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


PhorMed provided audited financials and increased their maximum funding goal.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Material Change in Offering

7 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


PhorMed updated the Directors and Officers, provided updated financials, and extended the duration of their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

8 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

11 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Phormed is extending its campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

11 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

12 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

PHORMED COLLABORATES WITH ABSORPTION SYSTEMS TO FURTHER COVID-19 AND PARKINSON’S TREATMENT

about 1 year ago

 

 PhorMed

Absorption Systems Collaboration Announcement

 

 

PhorMed will be entering into a collaboration agreement with Absorption Systems, a laboratory that will be conducting pre-clinical research in the COVID-19 and Parkinson’s disease areas. This partnership is also a key component in the company’s NIH grant application process. “We are very fortunate to solidify this partnership with a staff that has such extensive knowledgeable in the pre-clinical arena and a facility that is so well equipped, fulfilling many of our needs” said Ben Chang, Chairman of the Board. 

  

 

About Absorption Systems

Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. IDAS2, a novel in vitro test system for simultaneous screening of drug absorption and dissolution, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for formulation assessment. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Medford, MA, serves customers throughout the world. For information on the company's comprehensive contract services, applied research programs, and proprietary test systems, please visit www.absorption.com.

 

Notice of Material Change in Offering

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


PhorMed increased the length of their offering.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

PHORMED COLLABORATES WITH EMORY TO FURTHER PARKINSON’S TREATMENT

about 1 year ago

PhorMed

EMORY University Collaboration Announcement

 

PhorMed Inc (“PhorMed” or the “Company”) has entered into an agreement with Atlanta-based academic research leader Emory University for assistance in developing the Company’s proprietary drug for Parkinson’s disease. 

 

“Emory’s experts, with their extensive knowledge in Parkinson’s disease, will be a great addition to the PhorMed team and we look forward to a long and successful collaboration” said Dr. McCoy Moretz, the Chief Executive Officer of the company. 

 

 







About Emory University:


Emory University


LAST UPDATED: JANUARY 29, 2020


Founded in 1836, Emory University is a national center for teaching, research, and service, awarding more than 4,921 undergraduate and graduate degrees annually. It is recognized by U.S. News & World Report as one of the top 25 universities in the US (ranked 21st in the 2019 report). In 1966 the University’s Board of Trustees integrated all of Emory’s health components into the Robert W. Woodruff Health Sciences Center. The Woodruff Health Sciences Center joins those components of Emory University concerned with patient care, education of health professionals, research affecting health and illness, and policies for prevention and treatment of disease. Its components include schools of medicine, nursing, and public health; Yerkes National Primate Research Center; Winship Cancer Institute; Emory Global Health Institute, and Emory Healthcare, the most comprehensive health system in Georgia. 


See http://www.emory.edu/home/about/factsfigures/index.html

 

Funded Research at Emory


Researchers at Emory University received $734 million from external funding agencies in fiscal year 2018, marking a 17 percent increase over the previous year, with such funding having increased more than 50 percent over the past 10 years. Federal agencies awarded $440.8 million, or more than 60 percent of the total, led by the National Institutes of Health, with $359.2 million in awards. NIH funding represented nearly 82 percent of total federal dollars awarded to Emory.


See second article in http://whsc.emory.edu/publications/hs-update-archive/11-2018.html


And https://news.emory.edu/features/2018/11/record-research-funding/index.html


Notice of Funds Disbursement

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

PhorMed How It Works Video:

over 1 year ago

Our drug, RP-323, is a gene repair therapy that has the ability to repair damaged or mutated cells.

Please watch our video to learn more. 



Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Filing Status:

over 1 year ago

Our filing status is now current with the Securities and Exchange Commission. On May 4, 2020 we filed our C-AR, annual report, fulfilling our reporting obligations for securities sold pursuant to Regulation CF.

Notice to our investors:

over 1 year ago

We will be unable to meet our April 29, 2020, annual report filing requirements for securities sold pursuant to Regulation CF as a result of the officer in charge had contracted COVID-19 and was unavailable to meet the deadline.. As such, we intend to rely on the temporary relief being provided by the Securities and Exchange Commission. We will continue to use our best efforts to comply with our ongoing reporting obligations.

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

How Will PhorMed’s Drug Help COVID-19 Patients

over 1 year ago


How It Works

With PhorMed’s expanded pipeline adding “Anti-Virus and Suppression of Pulmonary Inflammation” to help fight COVID-19, PhorMed’s drug RP-323 will help people with compromised immune systems.   PhorMed’s goal is to assist the elderly and those with pre-existing conditions by boosting their immune systems and preventing fatalities among those patients who have contracted COVID-19.   



RP-323 has the ability to activate the body’s defense system boosting White Blood Cells (WBC) which include T-cell, B-cells, interferon, cytokines, antibodies and more. In clinical trials over 90% of patients using RP-323 had elevation of WBC, which is the primary need of people fighting COVID-19.  


Thank you all and be well,


McCoy Moretz, M.D., CEO

PhorMed Enters the Fight Against Coronavirus

over 1 year ago


PhorMed Expands Pipeline


  • On March 24, 2020 PhorMed entered into an assignment agreement to acquire a new indication for ANTI-VIRUS AND SUPPRESSION OF PULMONARY INFLAMMATION using RP-323.
  • PhorMed will collaborate with Professor Richard L. Chang to develop this Coronavirus COVID-19 fighting indication.
  • Professor Chang will share all data, existing protocols and FDA communications related to battling viruses.
  • A safety profile has already been submitted to the FDA.
  • This new collaboration expands our pipeline and ability to apply our platform technology to an additional indication.
  • PhorMed remains committed to patients suffering from diseases with little or no treatment options.


Thank you all and be well,


McCoy Moretz, M.D., CEO

Notice of Material Change in Offering

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

PhorMed Update March 6, 2020

over 1 year ago

Introduction

Although I have communicated with several of our investors on the Comment Board, I wanted to formally introduce myself. My name is Stuart Greene and I am the Director of Marketing and Business Development for PhorMed. It has been my pleasure to be welcomed as a part of the PhorMed family, and see the dedication to creating new treatment options for patients suffering from disorders where the traditional treatments like radiation and chemotherapy can be devastating in themselves, or where no real treatments are available in cases like Parkinson’s disease.

Clinical Site Announcement

I am excited to let you know that we are in final stages and have completed the legal review of our agreement with our clinical site. They are now working on the SOW and once that is completed, we will execute the agreement and will then announce their partnership. So please stay tuned for that announcement.

Campaign Status

Since the start of the campaign we were able to complete the initial raise of $107k, and subsequently increased our raise to the current $1.07m goal. Our campaign is ending in 5 days and we want to sincerely thank all of our investors and extend our gratitude for helping us to address these unmet medical needs. We look forward to continuing our efforts to offer hope for patients suffering from our targeted indications.

Thank you all and be well,

Stuart Greene

Director of Marketing and Business Development

Notice of Funds Disbursement

almost 2 years ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

almost 2 years ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

almost 2 years ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:


Phormed has increased its max funding goal and provided updated financials with an independent CPA review.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

almost 2 years ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}